PRMT5-介导的ALKBH5甲基化通过增加CD276表达促进结肠直肠癌免疫逃避
Sen Meng1,2, Hao Liu2, Jiayu Xu3
1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Research (Washington, D.C.)
|January 9, 2025
概括
蛋白质氨酸甲基转移酶5 (PRMT5) 通过通过ALKBH5修饰增强CD276表达来促进结直肠癌 (CRC). 针对这一轴,结合抗PD1疗法,显示了CRC治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 蛋白质氨酸甲基转移酶5 (PRMT5) 与许多疾病有关,包括癌症.
- 像GSK3326595这样的PRMT5特异性抑制剂正在进行癌症治疗的临床研究.
- 对于PRMT5在结直肠癌 (CRC) 进展中的确切作用尚未完全理解.
研究的目的:
- 阐明PRMT5促进结直肠癌恶性进展的机制.
- 研究PRMT5,ALKBH5和CD276在CRC中的相互作用.
- 评估针对CRC中的PRMT5-ALKBH5-CD276轴的治疗潜力.
主要方法:
- 使用生化分析研究了ALKBH5的PRMT5介导的修饰.
- 通过RNA分析评估ALKBH5对CD276表达和稳定性的影响.
- 评估了CD276上调对细胞毒性T细胞功能和CRC免疫逃避的影响.
- 利用体外和体内模型来研究CRC中的PRMT5-ALKBH5-CD276轴.
- 在CRC模型中检查了将PRMT5抑制剂与抗PD1抗体结合的疗效.
主要成果:
- PRMT5在R316 (meR316-ALKBH5) 中直接催化ALKBH5的对称二甲基化,促进其降解.
- 降低ALKBH5水平导致CD276mRNA在CRC细胞中的稳定性和表达增加.
- 上调的CD276抑制了细胞毒性T细胞的功能,有助于CRC免疫逃避.
- 通过PRMT5介导的meR316-ALKBH5增强了CD276表达和CRC免疫逃避,无论是体外还是体内.
- 在meR316-ALKBH5水平和CRC患者的不良结果之间存在强烈的相关性.
- 使用GSK3326595 (PRMT5抑制剂) 和抗PD1抗体的联合治疗显著阻止了CRC的进展.
结论:
- PRMT5通过meR316-ALKBH5-CD276轴促进CRC的进展和免疫逃避.
- 准PRMT5-meR316-ALKBH5-CD276通路代表了CRC的一个潜在的治疗策略.
- 联合抑制PRMT5和PD-1为治疗结直肠癌提供了一个有前途的方法.
更多相关视频
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
811
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K